Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer

2019306 citationsJournal Articlegold Open Access

Authors

Amar U. Kishan · University of California, Los Angeles

Audrey Dang · University of California, Los Angeles

Alan J. Katz · Flushing Hospital Medical Center

C.A. Mantz · 21st Century Oncology (United States)

Sean P. Collins · Georgetown University

Nima Aghdam · Georgetown University

Fang‐I Chu

Abstract

In this study, stereotactic body radiotherapy for low-risk and intermediate-risk disease was associated with low rates of severe toxic events and high rates of biochemical control. These data suggest that stereotactic body radiotherapy is an appropriate definitive treatment modality for low-risk and intermediate-risk prostate cancer.

Topics & Keywords

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Advanced Radiotherapy Techniques

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Network Open

Volume 2, Issue 2, pp. e188006-e188006

DOI: 10.1001/jamanetworkopen.2018.8006

Field-Weighted Citation Impact: 31.55